Conference Coverage

Be mindful of psoriasis/cutaneous T-cell lymphoma link


 

EXPERT OPINION FROM SDEF HAWAII DERMATOLOGY SEMINAR

Dr. Guy F. Webster

"Is the use of an anti-TNF agent going to increase that risk? The answer is that in all of the more than 2 million patients who’ve been treated with TNF inhibitors, there does not appear to be a statistical increase above the baseline risk," said Dr. Menter of Baylor University Medical Center, Dallas, and chair of the American Academy of Dermatology psoriasis guidelines committee.

SDEF and this news organization are owned by the same parent company. Dr. Menter, Dr. Gelfand, Dr. Webster, and Dr. Leonardi have received research funds and/or served as consultants to numerous pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Psoriasis Patients Have Low Rates of Common Cancers
MDedge Internal Medicine
Future lupus care challenged by researcher shortage
MDedge Internal Medicine
Smoking raises risk of active skin manifestations in SLE
MDedge Internal Medicine
PDE-5 inhibitors decrease secondary Raynaud's attacks
MDedge Internal Medicine
Pregnancies after vasculitis diagnosis are at risk
MDedge Internal Medicine
Systemic steroid prescriptions for psoriasis persist
MDedge Internal Medicine
Screen all psoriasis patients for hepatitis before immunosuppressive therapy
MDedge Internal Medicine
All glucocorticoids linked to increased risk of VTE
MDedge Internal Medicine
Obesity interferes with TNF-alpha inhibitors in psoriatic arthritis
MDedge Internal Medicine
Exceeding 10 mg/day prednisone increased CV events in lupus
MDedge Internal Medicine